New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
08:16 EDTAUXLAuxilium revenue outlook cut removes overhang, says Leerink
Leerink believes Auxilium's revenue outlook reduction is not surprising since Testim prescriptions have been declining 26% annually and 16% compared to last quarter. The firm says the news removes an overhang on the stock and points out that Testim represents only $1 of its $36 price target for shares. Leerink keeps an Outperform rating on Auxilium.
News For AUXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for AUXL

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use